Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

HIV drug resistance map: brazil study reveals why some treatments fail

NCT ID NCT07618507

Knowledge-focused Sponsor: Federal University of São Paulo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 777 people with HIV in Brazil who failed their first treatment with tenofovir, lamivudine, and dolutegravir. Researchers wanted to understand what types of drug resistance and virus subtypes were involved. The goal is to improve treatment choices for people in Brazil and similar countries.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tenofovir/Lamivudine and Dolutegravir
What this could lead to
If successful, this study could help doctors choose better HIV treatments for people in Brazil and similar countries by understanding which drug resistances are common.
What could go wrong
This is an observational study, not a test of a new treatment. It only looks at people who already failed therapy, so results may not apply to everyone with HIV.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

777 people

The number who actually took part.

Started

Apr 2022

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age between 18 and 70 ART therapy naive Exclusion Criteria: Resistant to reverse transcriptase inhibitor drugs (NRTI)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV HIV-1-infection

Contacts and locations

Locations

  • Centro Especializado em Doenças Infecciosas (CEDIN-DF)

    Brasília, Federal District, 70351-580, Brazil

  • Centro Estadual Especializado em Diagnóstico, Assistência e Pesquisa (CEDAP)

    Salvador, Estado de Bahia, 40100-160, Brazil

  • Fundação de Medicina Tropical Doutor Heitor Vieira Dourado

    Manaus, Amazonas, 69040-000, Brazil

  • Hospital Nossa Senhora da Conceição

    Porto Alegre, Rio Grande do Sul, 91350-200, Brazil

  • Hospital Santa Marcelina

    São Paulo, São Paulo, 08270-070, Brazil

  • LADI - Laboratório de Apoio Diagnóstico em Infectologia (Hospital Universitário Miguel Riet Corrêa Jr)

    Porto Alegre, Rio Grande do Sul, 90040-000, Brazil

  • Retrovirology Laboratory - UNIFESP

    São Paulo, São Paulo, 04039-032, Brazil

  • Serviço Especializado em IST/HIV/AIDS Viamão

    Viamão, Rio Grande do Sul, 94480-560, Brazil

  • Unidade de Infectologia William Rocha

    Guarujá, São Paulo, 11471-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.